Searchable abstracts of presentations at key conferences in endocrinology

ea0070aep346 | Diabetes, Obesity, Metabolism and Nutrition | ECE2020

Sodium taurocholate cotransporting polypeptide (NTCP) is a new and promising target for treatment of hypercholesterolemia: A proof of concept from a randomized double-blind placebo-controlled phase I trial

Zhu Zhenzhen , Fan Cuili , Zhu Shanwei , Wang Lizhen , Cai Fei , Gao Xian , Zhang Li , Tang Xiaolu , Liu Hongli , Wei Zhenman

Bile acids (BAs) are synthesized by converting cholesterol in hepatocytes and recycling it via enterohepatic circulation. Most BAs are reabsorbed into hepatocytes, where they inhibit their own synthesis by activating FXR pathway. NTCP is a major transporter of BAs via absorption from portal blood into hepatocytes. Hepalatide is a 47aa synthetic peptide that specifically binds NTCP resulting in BA spillover of hepatocytes into the systemic circulation. In this way, BA synthesis...

ea0073oc7.6 | Oral Communications 7: Diabetes, Obesity, Metabolism and Nutrition | ECE2021

NTCP is a new promising target for treatment of metabolic diseases: A proof of mechanism from double-blind phase I clinical trials of Hepalatide

Zhu Zhenzhen , Tang Xiaolu , Zhu Shanwei , Wang Lizhen , Gao Xian , Cai Fei , Zhang Li , Liu Hongli , Wei Zhenman

Bile acids (BAs) are potent signaling molecules that regulate glucose, lipid and energy homeostasis predominantly via farnesoid X receptor (FXR) and transmembrane G protein-coupled receptor 5 (TGR5). Modulation of bile acid profiles might affect the treatment of metabolic diseases, indicating new possible therapeutic avenues. The sodium taurocholate co-transporting polypeptide (NTCP) plays a pivotal role in the enterohepatic circulation of bile salts as the main uptake transpo...